Oesophageal Cancer

Oesophageal squamous cell carcinoma is one of the better-supported non-breast settings for shikonin.

Both cell-line and animal data exist.

That makes it stronger than many one-paper cancer pages.

Why oesophageal cancer is a logical target

ESCC shows strong Warburg-effect metabolism and high PKM2 expression.

STAT3 signalling is also commonly active and supports survival, proliferation, and treatment resistance.

Shikonin appears to pressure both through the same metabolic node.

Key evidence

In ESCC cell lines, shikonin:

• inhibited proliferation in a dose-dependent way

• reduced glycolytic activity

• suppressed STAT3 phosphorylation

• increased apoptotic markers

In xenograft models, shikonin significantly reduced tumour growth compared with control.

That is important because it shows the pathway story remains visible in vivo.

Why this matters

This is not just “another cancer type where shikonin kills cells.”

The relevance comes from a coherent PKM2-to-STAT3 pathway with both in vitro and in vivo support.

That gives oesophageal cancer a more solid place in the shikonin literature than many settings outside breast and bladder cancer.

Limits

• data is mainly in oesophageal squamous cell carcinoma, not adenocarcinoma

• no combination data with standard ESCC chemotherapy

• animal models were immunodeficient xenografts

• no human data exists

Bottom line

ESCC is one of the cleaner shikonin evidence areas outside breast cancer.

The mechanism is specific, replicated within the study system, and supported by animal work.

Clinical distance remains large.

The underlying rationale is still strong enough to watch seriously.

References

Lv C et al. (2021). Shikonin inhibits tumour growth of ESCC by suppressing PKM2-mediated aerobic glycolysis and STAT3. Journal of Cancer.
https://www.jcancer.org/v12p4830.htm